GlycoMimetics stock rockets up on the latest ‘breakthrough’ title in cancer R&D
Late last year Rockville, MD-based GlycoMimetics turned up at ASH to report out an early snapshot of some positive outcomes from the first stage of a Phase I/II study of GMI-1271, its E-selectin antagonist, for a small group of patients with acute myeloid leukemia. And with another batch of data being readied for ASCO in a couple of weeks, the biotech says that the FDA has helpfully provided a breakthrough drug designation to help them accelerate the development work through to a potential marketing application.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.